Skip to content

ICU Medical

US · ICUI #2287 by market cap Listed 1970
172.52 -3.24 -1.84%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 2.05 Expensive vs history 79th percentile
5-year average 1.84 · #19 of 51 in Medical Instruments & Supplies
P/E ratio 75.01 Expensive vs history 78th percentile
5-year average 159.93 · forward 36.66 · #23 of 27 in Medical Instruments & Supplies
P/S ratio 2.05 Expensive vs history 79th percentile
5-year average 1.86 · forward 1.99 · #19 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
ICU Medical (ICUI) 4.31B 72.18 1.97 0.00%
Intuitive Surgical (ISRG) 138.33B 48.25 8.65 0.00%
Becton Dickinson & Co (BDX) 57.96B 52.02 2.35 1.97%
Alcon (ALC) 35.92B 54.24 1.64 0.48%
ResMed (RMD) 33.14B 21.46 5.57 1.04%
Medline (MDLN) 32.55B 57.52 2.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value180.47 Economic moatNone UncertaintyMedium

Trading 4.6% below Morningstar's fair value estimate.

Fair value

ICU Medical Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a price consistent with our quantitative fair value estimate, which has a medium uncertainty rating.

The company's unfavorable dividend structure decreases our estimated valuation. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. Reflecting the firm's dividends is its forward dividend yield of 0%, which ranks in the bottom 30% globally. This could imply a planned dividend cut or relatively high share price, which contributes to our balanced fair value estimate.

The firm's liquidity is an additional cause for concern. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, for example, falls in the top 50% compared with peers globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. This characteristic further promotes our neutral price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is fairly-valued, this outperformance had a negative impact on our valuation estimate.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

ICU Medical discussion 0 comments

Add a comment